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SUMMARY
National health statistics report a 2.5-fold increase in laboratory-conﬁrmed Chlamydia
trachomatis (CT) cases over the last decade in Switzerland where no CT screening programme
exists. We obtained essential denominator information to describe the epidemiology of CT in the
canton of Basel-Stadt, an urban canton in north-western Switzerland. Laboratories reporting at
least two CT infections from Basel-Stadt residents to the SFOPH in 2010 provided demographic
and test-related data. CT positivity rates were calculated for 2002–2010. The inﬂuences of test
year, age, sex and laboratory on CT positivity were investigated in a multivariable model.
Positivity diﬀered between sexes and age groups. In our sample of 32 034 records, female and
male CT positivity rates were 4.7% and 11.1%, respectively. Test year was signiﬁcantly
associated with test outcome in the multivariable analysis but no time trend was observed.
CT positivity did not change over the past 9 years in Basel-Stadt. In contrast to other European
countries without CT screening, we found no evidence that the observed increase of Chlamydia
cases in the national notiﬁcation system represents an epidemiological trend, but rather results
from an increased testing frequency.
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INTRODUCTION
In Switzerland and other European countries, an in-
crease in sexually transmitted infections (STIs) has
been observed since the end of the 1990s [1]. The most
frequent bacterial STI, Chlamydia trachomatis (CT),
mainly aﬀects young adults with multiple sexual
partners not using condoms [2]. Treatment with anti-
biotics is eﬀective, but the frequently asymptomatic
nature of infections makes it diﬃcult to detect them
[3, 4].
The WHO estimated that 92 million people world-
wide were newly infected with CT in 1999, of which
ﬁve million were in Western Europe [5]. The epi-
demiology of CT infections in Switzerland cannot be
fully understood because existing studies on disease
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prevalence focus on selected risk groups such as
prisoners [6], undocumented immigrants [7] or men at
army recruitment [8].
Since 1988, laboratories are obliged by the Swiss
Epidemics Act to report positive Chlamydia test re-
sults to the Swiss Federal Oﬃce of Public Health
[SFOPH/Bundesamt fu¨r Gesundheit (BAG)] [9]. All
CT infections diagnosed by culture, genome (DNA/
RNA) or antigen detection from genital sites must be
reported. Currently, predominantly nucleic acid am-
pliﬁcation tests (NAATs) are used for the diagnosis of
CT infections [10]. Figures from the national notiﬁ-
cation system for infectious diseases (NNSID) indi-
cate a threefold increase of CT cases over the past
12 years [11]. Negative test results are not reported
to SFOPH and consequently no denominator data is
available for appropriate epidemiological trend
analysis. An increase in disease notiﬁcations is often
considered to reﬂect an increase in disease frequency.
We questioned this interpretation and hypothesized
that the observed increase of CT infections in oﬃcial
reports of infectious diseases is a consequence of
increased testing of diﬀerent target groups and does
not reﬂect an increase in disease frequency. Therefore,
we requested major diagnostic laboratories to provide
denominator data in order to calculate and interpret
positivity rates of CT in the canton of Basel-Stadt.
Basel-Stadt is one of 26 cantons of Switzerland
located in the northwest and considered to be urban.
The canton, with 193 627 inhabitants in 2010, 32%
of whom are non-Swiss citizens, consists of three
civil parishes. About 90% of the canton’s population
resides in the city of Basel, the third biggest city in
Switzerland [12].
METHODS
Positivity rate was deﬁned as the number of positive
tests divided by the total number of tests performed.
With our data, we cannot use prevalence or incidence
measures to describe the epidemiology of CT since the
denominator is the number of tests performed and
not the number of individuals tested. Hence, and in
accordance with other studies [10], we use the term
‘positivity’.
In 2010, a total of 13 laboratories reported CT
cases from residents of the canton of Basel-Stadt to
the SFOPH. Of those, seven laboratories reported at
least two CT cases from Basel-Stadt and were asked
to provide data on gender, year of birth, canton of
residence, test date, test result and test method of all
subjects tested for CT in the time period 2002–2010.
One private sector laboratory declined participation.
Four laboratories were from the private sector and
provided all requested information. Two were from
the public sector and provided complete data for the
years 2008–2010. The six laboratories were based in
four diﬀerent cantons of Switzerland (Basel-Stadt,
Basel-Land, Zu¨rich, St Gallen). Data from one lab-
oratory had to be entered into an electronic database
(Microsoft Access 2002, Microsoft Corporation,
USA). All other laboratories provided computerized
data.
One third of our data from Basel-Stadt was from a
public hospital laboratory even though this laboratory
only provided data for 3 years. Given the potentially
diﬀerent client and patient proﬁle in hospital labora-
tories, including those data in the analysis could
obscure a time trend in positivity rates. Therefore,
laboratories not providing data for the whole time
period were not included in the main analysis.
All collected data were analysed using Stata v. 10.1
(StataCorp., USA). Data analysis and statistical
testing was planned a priori. Univariable logistic
regression was used to assess whether test year, age
group, sex, laboratory and test method were signiﬁ-
cantly associated with the test result. We included sex
and age group and all variables that were signiﬁcantly
associated with the test outcome in the univariable
analysis at P<0.2 in a multivariable logistic re-
gression. Additionally we included an interaction
term for age group and sex in the multivariable mod-
el, because females might be infected at diﬀerent ages
than males. We decided not to stratify by sex as we
expected sample size to be too small, especially in the
male subject group.
The following groups were deﬁned as reference
categories : sex ‘male ’ ; age ‘o40’ ; test year ‘2010’ ;
laboratory ‘Lab D’; and test method ‘Cobas
Amplicor CT/NG test ’.
Inclusion criterion for records was residency of
patients in the canton of Basel-Stadt. Records with
missing test results were excluded. Records with miss-
ing age or sex were excluded in the logistic regression
model.
The univariable and multivariable analyses were
performed with the original dataset and repeated with
a cleaned dataset. In cleaning the data we identiﬁed
double entries and repeated tests. Records were
deﬁned as repeated tests if (i) they were from the same
patient entered on the same day from duplicate
samples and (ii) if two or more records had identical
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patient identiﬁcation numbers and a second test on
the same patient who tested positive was repeated
within 14 days after the initial test with no negative
test result in this period. In case of discordant test
results the positive result was retained in the analysis.
We calculated CT positivity rates for diﬀerent age
groups and sex. To assess the representativeness of
our data we compared the number of CT cases in our
data to the cases published by SFOPH.
To assess whether the relative testing frequency
between age groups remained constant over time we
performed multinomial logistic regressions stratiﬁed
by sex.
Ethical statement
This study used data from publically available sources
of the SFOPH or fully anonymized data from private
and public sector diagnostic laboratories.
RESULTS
In Switzerland, the number of notiﬁed Chlamydia
cases increased from 3111 (164 in Basel-Stadt) in 2002
to 6575 (259) in 2010 (Fig. 1).
We obtained 32034 laboratory records on CT
testing for the years 2002-2010 in the canton of Basel-
Stadt from six laboratories. Number of tests (and
positive tests) reported by the individual laboratories
were: 61 (6), 1236 (89), 3232 (187), 4089 (198), 11490
(350) and 11926 (665) over the study period. Our data
represent about 45% of the CT cases in Basel-Stadt
published every year by SFOPH (Table 1). Including
the tests performed by public laboratories in the
years 2008–2010, our data represent between
89% and 97% of the SFOPH-registered cantonal CT
cases.
Characteristics of laboratories and tested population
CT testing methods and test performance changed
over the study period. Two laboratories did not
change the method used for Chlamydia testing
during the study period, while two laboratories
changed once. However, all but one laboratory used
NAATs over the whole period (Table 2). All NAATs
applied by the participating laboratories detected
DNA of CT.
From 2002 to 2010 the number of tests performed
on Basel-Stadt residents increased substantially in
the four private laboratories (providing complete
data), totalling 1395 in 2002 and 3169 in 2010,
resulting in 67 and 155 Chlamydia-positive tests,
respectively.
Sixty-three (0.2%) records were excluded from
the overall analysis because of missing test results.
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Fig. 1. Absolute number of Chlamydia cases registered at SFOPH for the canton Basel-Stadt and Switzerland (lines) and
absolute number of Chlamydia cases (from Basel-Stadt) identiﬁed by participating laboratories (bars ; left axis) between 2002
and 2010. (Note : total numbers of Chlamydia cases reported by participating laboratories do not account for all cases
registered for Basel-Stadt at SFOPH.)
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In total, 50 (0.2%) records (two positive, 48 negative)
were not used for the logistic regression because of
missing information on age or sex.
Median age of patients tested was 30 years
(range<1–99 years) and diﬀered signiﬁcantly between
the laboratories (Kruskal–Wallis test, P=0.0001). Of
females, 74% of CT tests were performed in the
20–39 years group (Fig. 2). For males, the age distri-
bution peaked in slightly older age groups. More than
half (56%) of tests were performed on males aged
25–44 years.
While 54% of positive patients were aged
20–29 years, these represent only 38% of all tests
performed for both sexes within this age group.
Positive test results were found most frequently for
women aged 15–34 years and men aged 20–39 years.
Females were tested more often than males with
proportions tested for CT per year ranging from 80%
to 89% compared to 11–20% for men.
Positivity rates
CT was detected in 821/17558 female samples (4.7%)
and in 317/2849 male samples (11.1%). Figure 3
shows the time trend in positivity rates for sex and
laboratory. In both private and public sector labora-
tories, positivity rates were stable between 2002 (2008)
and 2010. However, the positivity rate in the public
hospital laboratories was lower than in the private
laboratories.
Univariable logistic regression revealed that sex,
age group, test year, laboratory and test method
Table 1. Absolute numbers of reported Chlamydia trachomatis cases in the canton of Basel-Stadt (2002–2010)
comparing laboratory-based* and SFOPH# records
2002 2003 2004 2005 2006 2007 2008 2009 2010
Cases recorded by SFOPH# 164 178 227 227 262 229 327 249 259
Cases reported by four private laboratories*$ 63 82 114 125 141 110 168 139 148
% reported by private laboratories 38% 46% 50% 55% 54% 48% 51% 56% 57%
Cases reported by two public sector laboratories$ 122 101 103
% reported by public sector laboratories 37% 41% 40%
Total number of cases reported by laboratories 63 82 114 125 141 110 290 240 251
% total reported 38% 46% 50% 55% 54% 48% 89% 96% 97%
* Data of two hospital laboratories were obtained for 3 years only and are, therefore, listed separately.
# SFOPH (Swiss Federal Oﬃce of Public Health), unpublished data.
$ Records classiﬁed as repeated tests were excluded (the time interval of 90 days between two tests was applied to make
numbers comparable to the SFOPH data source).
Table 2. Diagnostic method used to test for Chlamydia trachomatis
infections in participating laboratories
Laboratory Test method used
A 2002–2003: LCR* (external laboratory)
2002–2004: OIA# (BioStar OIA Chlamydia, Inverness Medical, UK)
2002–2010: PCR$ (external laboratory)
B kPCR· (Versant1 CT/GC DNA 1.0 assay, Siemens, Germany)
C PCR (Cobas Amplicor CT/NG test, Roche, USA)
D 2002–Jan. 2008: PCR (Cobas Amplicor CT/NG test, Roche, USA)
Feb. 2008–2010: PCR (Abbott Real Time CT/NG assay, USA)
E 2008–2010: PCR (Cobas Amplicor CT/NG test, Roche, USA)
F 2008–Feb. 2010: PCR (Cobas Amplicor CT/NG test, Roche, USA)
March–Dec. 2010: PCR (Abbott Real Time CT/NG assay, USA)
* Ligase chain reaction.
# Optical immune assay.
$ Polymerase chain reaction.
· Kinetic polymerase chain reaction.
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were signiﬁcantly associated with the test result at
the 20% signiﬁcance level (Table 3). Therefore, all
variables except ‘test method’ were included in the
multivariable analysis. The test method was excluded
because of partial collinearity with the variable
‘ laboratory’.
Adjusting for other factors, the year of CT testing
remained a signiﬁcant determinant of a positive test
result, although no clear time trend was observed. In
the years 2006 and 2008, the probabilities (odds) of
testing Chlamydia-positive were signiﬁcantly higher
than in 2010 (annual P values<0.05).
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Fig. 2. Test results according to age and sex of people living in Basel-Stadt, tested for Chlamydia trachomatis infection by
participating laboratories, 2002–2010. M, Males ; F, Females [records with missing test result (n=63) and records with
missing information on sex (n=13) are not shown].
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Fig. 3. Time trend in Chlamydia positivity rates in laboratories, by sex. Rates adjusted for age using direct standardization.
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The association between age and CT positivity was
modiﬁed by sex. In males, the adjusted odds ratios
(ORs) of testing positive were 2.58 [95% conﬁdence
interval (CI) 1.87–3.57], 4.54 (95% CI 3.31–6.22) and
1.96 (95% CI 0.94–4.09) for the 30–39, 20–29 and
15–19 years age groups, respectively, compared to the
Table 3. Factors associated with a positive test result for Chlamydia trachomatis in Basel-Stadt residents
(crude and adjusted odds ratios)
N* OR (95% CI) P value# aOR$ (95% CI) P value#
Sex 20 370 <0.0001 <0.0001
Male 2832 1 1
Female 17 538 0.39 (0.34–0.45) 0.26 (0.18–0.38)
Age group, yr 20 370 <0.0001 <0.0001
0–14 199 0.19 (0.03–1.38) —
15–19 1365 4.52 (3.50–5.83) —
20–29 7828 3.24 (2.63–3.97) —
30–39 6648 1.58 (1.27–1.98) —
o40 4330 1 —
Test year 20 370 0.018 0.050
2002 1392 0.96 (0.72–1.30) 0.93 (0.69–1.26)
2003 1526 1.17 (0.89–1.53) 1.12 (0.85–1.47)
2004 1941 1.27 (0.99–1.62) 1.21 (0.94–1.56)
2005 2193 1.23 (0.97–1.56) 1.21 (0.95–1.55)
2006 2272 1.32 (1.05–1.67) 1.30 (1.03–1.65)
2007 2420 0.97 (0.76–1.24) 0.96 (0.75–1.24)
2008 2639 1.37 (1.09–1.71) 1.33 (1.06–1.67)
2009 2828 1.05 (0.83–1.32) 1.08 (0.85–1.36)
2010 3159 1 1
Laboratory 20 370 0.009 0.038
A 1207 1.34 (1.07–1.69) 1.37 (1.08–1.74)
B 3230 1.04 (0.88–1.22) 1.12 (0.94–1.33)
C 4079 0.86 (0.73–1.01) 1.15 (0.97–1.36)
D 11854 1 1
Test method 20 370 0.035
Biostar OIA 46 0.39 (0.05–2.85) —
LCR 53 0.69 (0.17–2.85) —
PCR 1108 1.48 (1.17–1.88) —
Versant kPCR 3230 1.08 (0.92–1.28) —
Abbott PCR 4347 1.03 (0.88–1.20) —
Cobas Amplicor PCR 11586 1 —
Males aged, yr 2832 — <0.0001
0–14 79 — —
15–19 85 — 1.96 (0.94–4.09)
20–29 661 — 4.54 (3.31–6.22)
30–39 826 — 2.58 (1.87–3.57)
o40 1181 — 1
Females aged, yr 17 538 — <0.0001
0–14 120 — 0.51 (0.07–3.76)
15–19 1280 — 7.99 (5.69–11.21)
20–29 7167 — 4.76 (3.51–6.44)
30–39 5822 — 1.87 (1.35–2.60)
o40 3149 — 1
OR, Odds ratio ; aOR, adjusted odds ratio ; CI, conﬁdence interval.
* N, Number of observations (tests).
# From likelihood ratio test.
$ Adjusted odds ratio ; adjusted for sex, age group, test year, laboratory and sexrage group interaction.
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reference group (o40 years). Compared to females in
the o40 years age group, women aged 30–39, 20–29
and 15–19 years had adjusted ORs of 1.87 (95% CI
1.35–2.60), 4.76 (95% CI 3.51–6.44) and 7.99 (95%
CI 5.69–11.21), respectively. Female sex reduced the
probability of a positive test result by 74% (95% CI
62–82) (Table 3). None out of 79 boys (0–14 years age
group) tested for Chlamydia had a positive result and
1/120 tested girls of the same age group was found
positive.
Positivity rates of diﬀerent age groups stratiﬁed by
sex over the 9 years indicate that rates in females vary
only slightly across the years (Fig. 4). In contrast, in
males the positivity rates changed annually.
In Figure 5 we display the proportions of tests
performed by age groups and sex from 2002 to 2010.
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Fig. 4. Time trend in Chlamydia positivity rate in diﬀerent age groups, by sex.
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Results from the multinomial logistic regression
showed that the proportion of tests performed on
males in the 15–19 and o40 years age groups re-
mained stable over the 9 years (data not shown).
Compared to the o40 years age group, the pro-
portion of tests for males aged 0–14 and 30–39 years
decreased and the proportion of tests for males aged
20–29 years increased, but all of them not signiﬁ-
cantly. In females, the proportion aged 30–39 years
remained stable from 2002 to 2010 while the pro-
portion of the o40 years age group decreased mar-
ginally, the proportions of age groups 0–14 and 15–19
years decreased signiﬁcantly and that of females aged
20–29 years increased signiﬁcantly.
The logistic regression analysis was repeated after
exclusion of 63 (0.3%) records classiﬁed as repeated
tests. Results changed very little and interpretation
would not have changed at all. Therefore, we do not
show those results.
DISCUSSION
We investigated whether the observed increase in CT
case notiﬁcations during the past decade was asso-
ciated with increasing positivity rates. In contrast to
other European countries, in Switzerland there were
no oﬃcial screening programmes or national guide-
lines on CT testing and case management during the
study period from 2002 to 2010.
We found that CT positivity, even though signiﬁ-
cantly associated with year of testing, did not increase
between 2002 and 2010 nor did it exhibit a clear trend
in time. This phenomenon can be explained given
that the 2.5-fold increase in the absolute number of
CT cases observed in our data was accompanied by a
2.5-fold increase in the total number of Chlamydia
tests performed. Quality of test methods is assumed to
be very similar between laboratories without notably
changing during the study period as all but one lab-
oratory used NAAT techniques over the whole study
period. Those diagnostic methods have very similar
sensitivities and speciﬁcities. Nevertheless, diﬀerences
between laboratories exist and are likely to be linked
to diﬀerent client proﬁles ; in the hospital setting,
patients may be more likely to harbour a CT infection
(acute care for venereal complaints, lower socio-
economic status in outpatient units, higher pro-
portion of non-Swiss patients) than patients in private
practices (predominantly acute care and opportun-
istic testing during the periodical gynaecological
examination of low-risk groups). In contrast, in the
hospital settings, tests are prescribed in many in-
stances. Heterogeneity in test-prescribing behaviour
also exists among private practitioners [13]. Private
laboratories serve predominantly private practices.
The increase in absolute numbers of tests per-
formed over the years can be explained by increased
prescription of tests by physicians and to some extent
by an increase of overall testing volume within the
four laboratories. An increase in test prescriptions
may have diﬀerent underlying reasons: either test in-
clusion criteria used by the physicians changed over
time, leading to more people fulﬁlling those criteria.
If test prescription criteria remained unchanged, the
increase in the number of tests performed can be ex-
plained by a change in population behaviour with
more people meeting the same testing criteria.
Gender imbalance in chlamydial testing
Overall, 87.5% of CT tests over the past 9 years were
performed on women in the canton of Basel-Stadt.
Apart from symptom-based testing and treatment in
medical practice in both genders and more frequent
testing in risk groups, women are additionally tested
in Switzerland during regular gynaecological check-
ups, even though a Chlamydia test is not included
routinely. According to the Swiss Health Survey in
2007, 79.8% of women consulted a gynaecologist in
the preceding 2 years and 56.4% in the preceding 12
months. For men the frequency of interaction with an
urologist was unfortunately not assessed by the Swiss
national survey [14]. We presume that young men do
not routinely consult health services for medical
check-ups but rather seek help and contact a specialist
based on perceived morbidity, signs and symptoms. A
study in attendees of a sexual health clinic in New
Zealand found that asymptomatic patients seeking
STI testing were signiﬁcantly more likely to be
females than males [15].
A CT infection is more often asymptomatic in
females [2, 3]. Given diﬀerent help-seeking patterns
in males (symptom-based) and females (screening-
like), CT positivity, therefore, represents two diﬀerent
measures for males and females. For males, positivity
measures mostly acute infections (thus, resembling
incidence) while for females, positivity may rather
represent a prevalence measure; consequently, we are
dealing with two diﬀerent populations. However,
neither female nor male positivity rates represent
population prevalence or incidence rates since the
denominator does not equate the population at risk.
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Data from the NNSID reporting absolute case
numbers indicate that CT infections predominantly
occur in women (70%). This may further draw the
physician’s attention to seek for CT infections in
females. However, to conclude from this gender im-
balance in reported CT cases to a higher prevalence in
females could be misleading because the populations
tested diﬀer. Worldwide, there are several studies
showing no signiﬁcant gender diﬀerences in preva-
lence [16–18]. Furthermore, it is common practice
to treat sexual partners of infected patients without
testing. As females are tested more often, this may lead
to more (asymptomatic) male partners being treated
without testing and may, thus, account for under-
representation of male cases. Intensiﬁed testing in
women could be explained by more frequent testing of
risk groups such as pregnant women, women planning
contraceptive coil implantations or women under-
going surgical termination of pregnancy, as it is cur-
rent practice in health-care provision. Additionally,
Chlamydia morbidity due to long-term sequelae is
higher in females than in males [19]. Whether age at
ﬁrst sexual intercourse plays a role in observed gender
diﬀerences remains unclear. However, there is only
weak evidence that age at ﬁrst sexual intercourse is a
risk factor for chlamydial infection [20].
Positivity rates
Given the diﬀerential testing practice between males
and females, it is not surprising that there is a big
gender diﬀerence in positivity rates. Furthermore,
we do not know to what extent physicians treat
patients without testing and whether this is done dif-
ferentially for males and females. According to Paget
& Zimmermann STI diagnoses made by Sentinella
physicians were based on laboratory tests in only
40% of cases [21]. With the new national prevention
campaign for HIV and other STIs, the SFOPH pub-
lished case management guidelines for primary-care
physicians [22]. These recommendations consider
treatment of infections without laboratory conﬁr-
mation if a symptomatic diagnosis is conﬁrmative
or if the partner is treated for the same infection.
Moreover, ﬁnancial issues could play a role in treating
patients without laboratory conﬁrmation, especially
in young, non-pregnant adults. The yearly CT posi-
tivity rate varied without a clear time trend between
4.7% (2007) and 6.6% (2008). Bender et al. found
positivity rates in Denmark, Sweden and New
Zealand to be slightly higher and increasing over time
from about 5% in 1999 to 8% in 2008 [10].
Like Switzerland, these countries had no on-going
screening programmes but Chlamydia case manage-
ment guidelines existed, recommending Chlamydia
testing at least in one group of asymptomatic
patients. Comparable guidelines have only existed
in Switzerland since 2011. Even though screening
programmes or national guidelines can impact on
positivity rates, monitoring positivity rates is not
suﬃcient to evaluate the eﬀectiveness of such pro-
grammes or guidelines.
Positivity rates in young adults (aged <25 years)
tested during the ﬁfth year of the English National
Screening Programme (2007/2008) were 7.6% in men
and 9.3% in women. By contrast, in our sample
positivity rates in those aged 15–24 years were 18.1%
in men and 9.3% in women over the entire study
period. This substantial diﬀerence in men between the
two countries is probably explained by the diﬀerence
in testing practices. Such diﬀerences are not observed
in women suggesting that the current practice of CT
testing in Switzerland may resemble a screening-like
approach in the absence of an oﬃcial screening pro-
gramme. There is no evidence to assume a higher CT
prevalence in Switzerland than in the UK: popu-
lation-based prevalence was estimated at 0–4.9% in
the UK [23]. The prevalence in Swiss men at army
recruitment was 1.2%, the most accurate prevalence
estimate available for young men aged between 18
and 26 years in Switzerland [8]. A study by Swiss
sentinel gynaecologists found a prevalence of 1.3% in
pregnant women and 2.8% in women who went for a
gynaecological check-up [24].
From a 1-year laboratory-based Swiss study in
2009 we calculated a CT positivity rate of 4.0% in
females and 6.4% in males [25]. These ﬁgures are
comparable to our observed positivity rates of 4.5%
in females and 10.2% in males in 2009.
Testing practices
A stable positivity rate does not necessarily mean that
incidence is stable and, vice versa, an increasing
positivity rate could occur without a true increase in
incidence. All those measures highly depend on test-
ing practices of physicians and on the population
tested.
We calculated positivity rates because we have dif-
ferent test groups (males representing rather incidence
and females as a proxy for prevalence) and cannot
conclude on the true epidemiological situation.
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In order to equate the trend in positivity rates with
trends in prevalence or incidence rates we would need
to assume that the testing practice in the two groups
as well as sexual risk behaviour remained constant
over time. We only have data on age and sex to in-
vestigate this assumption. Figure 5 describes the
relative testing frequencies in each age group. For
males, relative testing frequency did not change across
age groups. However, in females, there was a tend-
ency over the observed 9-year period to perform more
tests in one age group (20–29 years) and less in others
(0–14, 15–19, o40 years). It is, therefore, possible
that the target population for Chlamydia tests chan-
ged, especially in females, which in turn leads to dif-
ferent pre-test probabilities of being infected. This
could mean that the trend observed in the positivity
rate could diverge from the trend of the real CT inci-
dence (males) or CT prevalence (females). The latter
two can only be obtained from random population-
based surveys.
Median age of negatively tested persons was
31 compared to a median age of 26 years in positively
tested persons. An explanation for this diﬀerence
in median age is that pregnant women are tested
frequently and only up to 38% of live births in
Switzerland occur in mothers aged 20–29 years, while
as many as 60% of live births occur in those aged
30–39 years [12].
Treatment and repeated testing
We could identify only 63 (0.3%) records as repeated
tests considering a second CT test performed within
14 days as a repeated test. Excluding these from the
analysis did not change the interpretation of the re-
sults. Similarly, applying the SFOPH criteria of a time
interval of 90 days diﬀerentiating a repeated vs. a new
infection did not change the results (data not shown).
Repeated infections are not likely to be due to
treatment failure. The most commonly used anti-
biotics for CT therapy (azithromycin, doxycycline)
have been shown to be equally eﬃcacious with cure
rates of 97–98% [26]. Therefore, persistent infections
are more likely due to compliance issues or immediate
re-infection because of on-going sexual contacts with
infectious partners. Further, persistence of DNA
from dead chlamydial bacteria may lead to false-
positive results for up to 3 weeks following treatment
[27–29].
Our study has some limitations. We enrolled six of
seven major laboratories into the study. However,
two laboratories could not provide data for the whole
time period and were, therefore, excluded from the
main analysis. Even though our data represent only
half of the cantonal Chlamydia infections reported to
SFOPH, our data are likely to reﬂect the situation in
Basel-Stadt. This is consistent with the ﬁndings from
the regression model using data from all six labora-
tories for the years 2008–2010: the positivity rate did
not change in the past few years in Basel-Stadt.
Interpretation of the total number of CT tests
performed is hampered because the increase of CT
testing could be a consequence of structural growth of
individual diagnostic laboratories, thus, of increased
overall testing volume rather than of an increased CT
testing frequency. This is supported by the fact that
participating laboratories reported higher percentages
of CT cases to SFOPH over time (Table 1).
Repeated tests could not always be identiﬁed as the
Swiss health information system does not (yet) utilize
unique patient identiﬁcation numbers. The use of test
methods of diﬀerent sensitivities and speciﬁcities in
laboratories could explain some of the variation be-
tween diagnostic laboratories ; however, choice of CT
test material, i.e. urine, urethral or vaginal swab may
have a larger impact on the sensitivity and speciﬁcity
of test outcomes than the choice of a NAAT method
[25]. The recent use of a combined CT and Neisseria
gonorrhoea test could also potentially result in a rising
detection rate of CT infections and, therefore, in in-
creasing numbers of cases as observed in the NNSID.
Additional CT diagnoses resulting from a simul-
taneous testing for CT and N. gonorrhoea, as done in
one private and one hospital laboratory, could not
be identiﬁed. Finally, test-prescribing behaviour of
physicians relating to the control of treatment out-
come, screening of pregnant women or other ‘risk’
groups, or as an eﬀect of national control endeavours
may have changed over time. The 2009 Swiss HIV/
AIDS prevention campaign called ‘LOVE LIFE STOP
AIDS ’ (www.lovelife.ch) did not have a measurable
impact on Chlamydia positivity rates in 2009/2010.
Messages on STIs in general and chlamydial infec-
tions in particular are only explicitly featured in the
subsequent recent campaign in 2011 (‘LOVE LIFE’ ;
www.lovelife.ch).
CONCLUSION
Data from the NNSID provide no denominator
data on CT and other infectious diseases limiting
epidemiological interpretation of publically available
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health information. Considering denominator data
from diagnostic laboratories for residents of the can-
ton of Basel-Stadt, the observed increase of CT cases
in the NNSID may not reﬂect a higher frequency
of this notiﬁable sexually transmitted infection.
We found no increase in Chlamydia positivity in
Basel-Stadt over the past 9 years.
Studies from European and other countries, without
screening for CT (similar to Switzerland), suggest a
true increase of CT positivity rates. This contrasts with
the ﬁndings of our study and underscores the necessity
of obtaining comparable CT data for other Swiss
cantons to conclude on recent epidemiological patterns
of CT infections for the whole of Switzerland.
This study has shown that great caution is needed
when interpreting changes in numbers of disease no-
tiﬁcations without knowing the denominator.
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